Highlights of This Issue 1877

SPECIAL FEATURES

CCR Translations

1879 Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
Elad Sharon
See related article, p. 1920

CCR Perspectives in Regulatory Science and Policy

1882 FDA’s Approach to Regulating Biosimilars
Steven J. Lemery, M. Stacey Ricci, Patricia Keegan, Amy E. McKe, and Richard Pazdur

CCR Drug Updates

1886 Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Brant A. Inman, Thomas A. Longo, Sundhar Ramalingam, and Michael R. Harrison

Molecular Pathways

1891 Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Amy Walz, Andrey Ugolkov, Sunandana Chandra, Alan Kozikowski, Benedetto A. Carneiro, Thomas V. O’Hallowan, Francis J. Giles, Daniel D. Billadeau, and Andrew P. Mazar

CANCER THERAPY: CLINICAL

1898 Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

1910 A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, and Michaela Banck

1920 Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stéphane Champiat, Laurent Derce, Samy Ammari, Christophe Massard, Antoine Hollebeque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggemont, Aurélien Marabelle, Jean-Charles Soria, and Charles Ferté
See related commentary, p. 1679

1929 Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

1937 Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Suresh S. Ramalingam, Normand Blais, Julien Mazières, Martin Reck, C. Michael Jones, Erzsébet Juhász, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keilholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dzubielski, Hao Xiong, Peter Amell, Mark McKe, Vincent Giranda, and Vera Gorbonova

1945 A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981</td>
<td>Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma</td>
<td>James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Amy F. Buros, James A. Ntambi, Sarah Waheed, Frits van der Heijden, Maurizio Zangari, Christoph J. Heuck, Nathan Petty, Carolina Schinke, Sharmilan Tanveer, Alan Mitchell, Antje Hoering, Bart Barlogie, Rachel Morgan, and Faith E. Davies</td>
</tr>
<tr>
<td>1998</td>
<td>Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum</td>
<td>Alicia Hulbert, Ignacio Jusue-Torres, Alejandro Stark, Chen Chen, Kristen Rodgers, Beverly Lee, Candace Griffin, Andrew Yang, Peng Huang, John Wrangle, Steven A. Belinsky, Tza-Huei Wang, Stephen C. Yang, Stephen B. Baylin, Malcolm V. Brock, and James G. Herman</td>
</tr>
<tr>
<td>2010</td>
<td>The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer</td>
<td>Yufang Ma, Lihong Wang, Leif R. Neitzel, Sudan N. Loganathan, Nan Tang, Lili Qin, Emily E. Crispi, Yan Guo, Stefan Knapp, R. Daniel Beauchamp, Ethan Lee, and Jialiang Wang</td>
</tr>
<tr>
<td>2019</td>
<td>A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon</td>
<td>Kang-Jian Zhang, Xiao-Fei Yin, Yuan-Qin Yang, Hui-Ling Li, Yan-Ni Xu, Lie-Yang Chen, Xi-Jun Liu, Su-Jing Yuan, Xian-Long Fang, Jing Xiao, Shuai Wu, Hai-Neng Xu, Liang Chu, Kanstantsin V. Katlinski, Yuliya V. Katlinskaya, Rong-Bing Guo, Guang-Wen Wei, Da-Cheng Wang, Xin-Yuan Liu, and Serge Y. Fuchs</td>
</tr>
</tbody>
</table>
BIOLOGY OF HUMAN TUMORS

2061  Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer
Qiaoyi Liang, Jonathan Chiu, Yingxuan Chen, Yanqin Huang, Akira Higashimori, Jingyuan Fang, Hassan Bitrin, Hassan Ashktorab, Siew Chien Ng, Simon Siu Man Ng, Shu Zheng, Francis Ka Leung Chan, Joseph Jao Yiu Sung, and Jun Yu

2071  A Positive Feedback Loop of IncRNA-PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Mi-die Xu, Yiqin Wang, Weiwei Weng, Ping Wei, Peng Qi, Qiongyan Zhang, Cong Tan, Shujian Ni, Lei Dong, Yusi Yang, Wannun Lin, Qinghua Xu, Dan Huang, Zhaohui Huang, Yuqing Ma, Wei Zhang, Weiqi Sheng, and Xiang Du

2081  Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer
Anna Bachmayr-Heyda, Stefanie Aust, Katharina Auer, Samuel M. Meier, Klaus G. Schmetterer, Sabine Dekan, Christopher Gernez, and Dietmar Pils

2093  Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
Priyadharsini Nagarajan, Jonathan L. Curry, Jing Ning, Jin Piao, Carlos A. Torres-Cabala, Phyu P. Aung, Doina Ivan, Merrick I. Ross, Charles F. Levenback, Michael Frumovitz, Jeffrey E. Gershemwald, Michael A. Davies, Anaiz Malpica, Victor G. Prieto, and Michael T. Tetzlaff

2105  Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma

2116  Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer

CORRECTION

2127  Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a primary tumor from mice harboring activated Braf and inactivated Pten in melanocytes that developed a genetically induced melanoma tumor. The staining shows aggressive tumor growth in animals treated with vehicle (as opposed to those treated with novel recombinant sIFN-I interferons). For details, see the article by Zhang and colleagues on page 2038 of this issue.